An arousal level control apparatus calculates a setting value of a control device under a constraint condition using an arousal level optimization model so that a value of an objective function is maximized. The control device affects a physical quantity of a surrounding environment that affects arousal level of a subject. The arousal level optimization model includes the constraint condition and the objective function. The constraint condition includes a physical quantity prediction model, an arousal level prediction model, and a setting value range condition that the setting value is within a predetermined range. The physical quantity prediction model is an explicit function that includes the physical quantity and the setting value as explanatory variables and has a predicted value of the physical quantity as an explained variable.

The present invention is a device that will properly position a respiratory face mask on a user's face and reduces the likelihood that it will slip downward off the subject's nose exposing the wearer's nostrils and negating the mask's intended purpose of stopping the transmission of airborne diseases.

The present invention is a handheld device used to deliver hyaluronic acid to the skin and is used in the dermatology field and as an aesthetic treatment. The present invention uses pressure to launch a hyaluronic acid mixture into the skin that is better tolerated and less painful than conventional hypodermic needle procedures. The present invention is a non-invasive tool that delivers hyaluronic acid into the skin through the use of pressure as opposed to a hypodermic needle, thereby significantly decreasing the likelihood of damage to the skin when compared to a hypodermic needle device.

Module for housing electronic and electromechanical medical equipment including a portable digital camera and processing circuitry with machine vision and machine learning software for automatically documenting healthcare events and healthcare equipment operations in the electronic health record.

A collapsible healthcare barrier device may be moveable between collapsed and erected positions. The device may include a left side panel, a front panel, a right side panel, and a top panel. The left side panel is hingedly connected to the left side of the front panel. The right side panel is hingedly connected to the right side of the front panel. The top panel is hingedly connected to the top of the front panel. The front panel includes at least one passageway through which a health care provider may extend his or her hands and arms to render care to a patient. The top panel may include a left lip member and a right lip member. A back flap may be hingedly connected to the rear of the top panel. The back flap may include a left wing member and a right wing member.

Face soaking devices (devices) may include a vessel and a vessel neck gasket. The vessel may be configured to hold a liquid to submerge a face of a user or a portion thereof. The vessel neck gasket may be (removably) joined to the vessel. The vessel neck gasket may be configured to comfortably accommodate a portion of the user's neck. The devices may include a breathing apparatus that may be in removable contact with: the vessel, with a head rest subassembly, and/or with the user. The breathing apparatus may be configured to permit the user to breathe while the user's face may be submerged within the liquid. When the vessel may be filled with the liquid to at least a sufficient level, the user may soak the face or the portion thereof, such that the skin being soaked receives a benefit.

The present invention relates to a medical treatment device for stimulating neurons of a patient. The device comprises a first non-invasive stimulating device for generating at least two different first stimuli to a patient's body, a second non-invasive stimulating device for generating at least two different second stimuli to the patient's body, and a control unit for selectively and intermittently actuating the stimulating devices. In a first operating mode, the control unit is configured to actuate the first stimulating device in a sequence of successive actuating periods such that a number n of first stimuli to be generated simultaneously during the actuating periods is variedly determined across the sequence and to actuate the second stimulating device so as to generate the second stimuli to be paired to the generation of at least a part of the first stimuli. In a second operating mode, the control unit is configured to actuate the second stimulating device so as to generate the second stimuli to be de-coupled from the generation of at least a part of the first stimuli.

A patient interface includes a first body that rests on a first portion of a patient's face, a second body that rests on a second portion of the patient's face, and a bridge linking the first and second bodies. The patient interface includes an attachment structure that couples with a complementary fixation structure positioned on the patient's face to secure the patient interface to the patient's face. The complementary fixation structure can be configured to assist in retaining a feeding tube in position relative to the patient's face or to the patient interface.

The present invention provides devices and methods for creating and/or maintaining patency of the upper airway passage. The device is configured to fit under the chin of a subject at an external location corresponding approximately with the subject's internal soft tissue associated with the neck's anterior triangle. The device includes structural elements designed to optimize comfort, compliance and seal achieved through minimizing the pressure variation along the contact surface of the therapy device.

Embodiment provided herein are directed to microneedle patches for agent application on a mammal skin. The microneedle patch may comprise a patch scaffold having a surface, and a plurality of microneedles disposed on the surface. Each of the microneedles may be capable of piercing the skin 50 μm to 1000 μm deep, and comprises a composite material comprising polyvinylpyrrolidone (PVP) and one or more additional copolymers selected from the group consisting of maltose, leucine, and dileucine.